Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Monopar Therapeutics Inc.NASDAQ: MNPR
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns positive
Q1 FY2026 Accumulated OCI was $98.52K, compared with -$21.78K a year earlier. Over 3 fiscal years it compounded at +144.9% a year.
Context
- Accumulated OCI amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +552.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 131.39K USD
- Year-over-year change
- +265.1%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 131.39K | +265.1% |
| FY2024 | 2024-12-31 | 35.99K | +354.7% |
| FY2023 | 2023-12-31 | (14.13K) | -258.0% |
| FY2022 | 2022-12-31 | 8.94K | +383.0% |
| FY2021 | 2021-12-31 | (3.16K) | — |
Accumulated OCI vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +552.3% is the 2nd highest of 9, against a peer median of -222.5%.
- Accumulated OCI amounts to 0.1% of total assets for MNPR, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €1.12M EUR | +4040.7% | +10.9% | 1.8% | |
| Mar 2026 | $98.52K USD | +552.3% | +144.9% | 0.1% | |
| Mar 2026 | -$27K USD | -2600.0% | — | 0.0% | |
| Jun 2026 | -$60K USD | — | — | 0.1% | |
| Mar 2026 | -$159K USD | -183.7% | — | 0.1% | |
| Mar 2026 | -$245K USD | -307.6% | — | 0.1% | |
| Sep 2026 | -$467K USD | — | — | 0.1% | |
| Mar 2026 | -$802K USD | +26.6% | — | 0.3% | |
| Jun 2026 | -$872K USD | -438.0% | — | 0.1% | |
| Mar 2026 | -$5.28M USD | -261.3% | — | 0.8% | |
| Sep 2026 | -$6.66M USD | -10.1% | — | 0.6% | |
| Peer median (excluding MNPR) | — | -222.5% | +10.9% | 0.1% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.